December 11, 2020
Solid Biosciences (SLDB) executes a $90 M Private Placement
December 2, 2020
Intellia Therapeutics (NTLA) prices 4.79 million share offering at $36.50
November 4, 2020
Bellicum Pharmaceuticals (BLCM) closes 1.04 M share offering
August 12, 2020
Adverum Biotechnologies (ADVM) closes $216.8 million offering priced at $3.00
July 8, 2020
BioLife Solutions (BLFS) closes 5.95 million share offering priced at $14.50
July 2, 2020
MiMedx Group (OTC PINK: MDXG closed $150 million private equity and debt financings
June 26, 2020
Editas Medicine (EDIT) closes 6.9 million shares offering at $31.25
June 11, 2020
Fate Therapeutics (FATE) completes 7,108 M share offering at $28.31 for proceeds of $201.3 million
June 6, 2020
Intellia Therapeutics (NTLA) closes $115 million offering
May 26, 2020
Caladrius Biosciences, Inc. (CLBS) closes RDO (registered direct offering) of 2.084 million shares priced at $2.06
May 19, 2020
bluebird bio (BLUE) proposes 9.09 M share offering priced at $55.00
May 13, 2020
Mesoblast (MESO ASX: MSB) completes US$90 M private placement of 43 M shares
March 6, 2020
BrainStorm Cell Therapeutics (BCLI) $10 M registered direct offering (RDO) priced at $8.00
February 28, 2020
Verastem (VSTM) offers 46.5 M private placement priced at $2.15 valued at $100 M to institutional investors
August 19, 2019
Bellicum Pharmaceuticals (BLCM) prices 575 K preferred stock share and warrant offering at of $100.00
August 8, 2019
Stemline Therapeutics (STML) proposes 5 M share offering
April 8, 2019
Histogenics (HSGX) reverse mergers with Ocugen, Inc.
February 26, 2019
Ultragenyx Pharmaceutical (RARE) prices a 5.072 M share offering at $60.00
February 26, 2019
Sage Therapeutics (SAGE) prices 3.33 M share offering at $150.00
January 16, 2019
Stemline Therapeutics (STML) priced an 8.88 M share offering at $9.00 per share
January 15, 2019
Alnylam Pharmaceuticals (ALNY) priced 5 M share offering at $77.50
December 7, 2018
Global Blood Therapeutics (GBT) Prices a $150 M offering at $44.00 per share
October 26, 2018
Neuralstem (CUR) $2.1 M is executing a $2.1 M or 3 M share RDO priced at $0.70
October 14, 2018
Verastem Oncology (VSTM) priced a $150 M offering of 5% Convertible Senior Notes in a registered direct offering
October 10, 2018
Audentes Therapeutics (BOLD) proposed a 5.2 M share offering with a 780 K share overallotment priced at $29.00
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2023 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.